Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesConference Call and Webcast Today at 4:30 p.m. ET

Print Friendly, PDF & Email

RETT SYNDROME RELATED: (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2020. Christopher U […]